The RECUR initiative is a collaborative effort involving the American Society for Transplantation and Cellular Therapy, the Association of American Cancer Institutes, and the Association of Community Cancer Centers

CGI has recently unveiled a strategic collaboration with Körber to enhance the production processes within the pharmaceutical and life sciences sectors. This partnership aims to integrate

Verastem Oncology xhas been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its investigational RAF/MEK clamp, avutometinib, in combination with Amgen’s KRAS G12C inhibitor,

CAR T Global Consultant Inc., a specialized consulting company in the realm of Cell & Gene Therapy, is thrilled to unveil its latest offering—a Contract Cell & Gene Therapy Organization

Eisai Co., Ltd. has recently received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for its injection formulation of the antiepileptic drug Fycompa® in Japan. This approval allows for the use of Fycompa as an alternative therapy

Compass Pathways plc and Hackensack Meridian Health have recently entered into a research collaboration agreement to enhance the design of the delivery model for investigational

BIOSENIC, a clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, have announced the signing of a binding

WuXi Biologics , a globally recognized Contract Research, Development, and Manufacturing Organization, has recently inked a research service agreement

Xcell Biosciences, Inc, a company specializing in platform technology for cell and gene therapy applications, has recently announced a collaboration with ElevateBio, LLC. The partnership aims

Walden Biosciences, Inc, a private biotechnology company concentrating on revolutionizing the treatment of kidney disease